Bruntsch U, Gallmeier W M
Strahlentherapie. 1977 May;153(5):325-30.
Ovarian carcinomas are highly sensitive to chemotherapy. The alkylating agents were most extensively investigated. With these drugs remissions can be obtained in about 50% of the patients. Some early results seem to show a higher response rate and a longer duration of remission after combination chemotherapy. In ovarian carcinoma it has to be the aim of the chemotherapy to obtain a complete remission. The indications for chemotherapy are not yet well defined. Treatment is definitely indicated in stage IV (FIGO) or in recurrent disease after radiotherapy. This treatment has to be given as a long-term therapy over a long period of time. In stage III and II b disease a combined treatment plan has to be developed by the radio- and chemotherapist. At the present time no data are available which prove or disprove the value of an adjuvant chemotherapy in the early stages of ovarian carcinoma. Remembering the somewhat promising results of adjuvant chemotherapy in breast cancer, it is conceivable that prophylactic chemotherapy will prove to be indicated in early stages of ovarian carcinoma.
卵巢癌对化疗高度敏感。烷化剂是研究最为广泛的药物。使用这些药物，约50%的患者可实现缓解。一些早期结果似乎显示联合化疗后的缓解率更高，缓解期更长。对于卵巢癌，化疗的目标必须是实现完全缓解。化疗的指征尚未明确界定。IV期（国际妇产科联盟[FIGO]分期）或放疗后复发的疾病肯定需要进行治疗。这种治疗必须作为长期疗法持续很长时间。对于III期和IIb期疾病，放疗师和化疗师必须制定联合治疗方案。目前尚无数据证实或反驳辅助化疗在卵巢癌早期的价值。鉴于辅助化疗在乳腺癌中取得了一些有希望的结果，可以想象预防性化疗在卵巢癌早期可能会被证明是必要的。
